Publix heiress known for philanthropy dies in Florida at 65
The billionaire daughter of the Publix Super Markets founder has died after having early-onset Alzheimer's Disease, the company announced Wednesday. Carol Jenkins Barnett was 65. Barnett died Tuesday night at her home in Lakeland, Florida, Publix said in a news release.news.yahoo.com
2 Asian American women stabbed in San Francisco attack
Police arrested a man who they say is suspected of stabbing two Asian American women without warning Tuesday afternoon in San Francisco's Mid-Market area. A 54-year-old San Francisco man was arrested on suspicion of committing the attack several hours later, police told the station. Asian Americans have been the target of several unprovoked attacks in the San Francisco Bay Area in recent months.news.yahoo.com
Drug shows promise in treating Alzheimer’s
FORT LAUDERDALE, Fla. – In spite of years of research, treatments for Alzheimer’s disease have not been promising, until recently. Dr. Hazel Wiley with the Memory Disorder Center at Broward Health North said a small clinical trial showed a reduction in amyloid plaques in the brain, a key component of Alzheimer’s disease. Wiley underscored that many other drugs have tried, and failed, to achieve the same result and that this current Phase 2 trial was very small. The study still needs to move on Phase 3 human trials in order to be considered for approval by the Food & Drug Administration, which could take at least 2 years. Data on the benefit of CBD oil continues to expand, concluding now evidence that it could be helpful in treating a variety of skin conditions.
New model may better detect Alzheimer’s from early cognitive changes
WESTON, Fla. – Scientists are reporting a new and non-invasive model for predicting Alzheimer’s disease in people with moderate impairment. Dr. Damon Salzman, a neurologist with the Cleveland Clinic Weston, said the importance of the new model is its potential to determine which patients with mild cognitive impairment might progress to full Alzheimer’s. The model combines two blood tests that look for particular proteins connected to Alzheimer’s. Salzman said 50 to 80 percent of patients with mild cognitive impairment develop Alzheimer’s, so the test could help determine who would be best suited for early intervention therapies to slow the progression of the disease. If you suffer from achy feet at night, it may not be just because you stand or walk a lot during the day.
Upcoming Alzheimer’s walk underscores need for treatment advancements
Mabel-Faye Solomon was a bright, active retired teacher who loved to dance and she was the light of her daughter Michelle’s life. Solomon herself became that “somebody else” by serving as the mission chairperson for the Broward Walk to end Alzheimer’s for the past 5 years. The Broward Walk To End Alzheimer’s is being held virtually this year with a virtual stage that you can log in and watch ceremonies starting at 9 a.m . Find our more about the Broward Walk by clicking here. For anyone who needs help or support for a loved one with Alzheimer’s disease or another form of dementia, call the Alzheimer’s Association at (800) 272-3900.
Test for Alzheimers ‘focuses’ on the eyes
MIAMI – The number of Americans living with Alzheimer’s is growing, and along with efforts to develop effective treatments for the disease, researchers are looking into ways to more easily diagnose it at an early stage. Since 2015, Dr. Delia Cabrera DeBuc with the Bascom Palmer Eye Institute has been working to develop an eye test that could identify biomarkers that are indicative of Alzheimer’s. DeBuc’s research isn’t just about science, it’s also personal; a year ago she tested positive for the late on-set Alzheimer’s gene. The study, published in the journal Science found that even people who did not have COVID-19 had antibodies against the virus in some of the samples tested. Researchers theorize that exposure to any of the common human coronaviruses, including the common cold, may lead to some level of immunity against COVID-19.
Study examines Alzheimer’s disease and ethnicity
MIAMI, Fla. – Researchers at the University of Miami have identified new gene risks for Alzheimer’s Disease among African-Americans. While there are similarities across populations, a recent study specifically analyzed data collected from over 8,000 African-Americans. “This is important because we are trying to determine the biologist and get a better understanding of the biology. In other health news, a recent study suggests that people with Type-2 diabetes might be able to reduce their mortality risk by drinking coffee and green tea. Because the study was observational, it’s not possible to prove that green tea and coffee reduce the odds of dying, only that consuming these beverages is associated with lower odds.
Biogen's stock rises 4% after company releases new data on late-stage Alzheimer's drug
The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019. Biogen shares rose Thursday after the biotech firm offered more data on its late-stage Alzheimer's drug, aducanumab. The data, presented at the Clinical Trials on Alzheimer's Disease conference, offered almost no new results from what the company previously released in October. Dr. Eric Siemers, an Alzheimer's expert who previously led Alzheimer's research at Eli Lilly, also noted the company offered a more detailed look but "almost the same as they showed" previously. Prior to the announcement, Biogen shares were halted at $286.83.cnbc.com
Biogen's stock could fall 10% on new Alzheimer's drug data this week, top analyst says
Biogen's stock could fall as much as 10% once it releases new data this week on its Alzheimer's drug, aducanumab, Baird biotech analyst Brian Skorney told CNBC on Monday. Shares of Biogen were down more than 2% in intraday trading Monday after Skorney wrote in a note to investors that he is skeptical Biogen's Alzheimer's drug will be approved by federal regulators. In March, Biogen pulled the plug on its Alzheimer's drug and sent its stock tanking after an analysis from an independent audit revealed the experimental medicine was unlikely to work. Biogen's drug targets a compound in the brain known as beta-amyloid, which is thought to play a role in the devastating disease by eroding synapses between nerve cells. Biogen is expected to release new data for its drug at the Clinical Trials on Alzheimer's Disease annual congress on Thursday.cnbc.com
Man finds out mother's body sold to military and detonated
PHOENIX - A man who donated the body of his late mother to a research center to learn more about Alzheimer's was devasted to learn the truth about where her body ended up. Jim Stauffer's mother Doris died five years ago after spending the final years of her life suffering from Alzheimer's Disease. Because Doris didn't have the gene for the disease, doctors were interested in studying her brain, but were unable to accept the body. Instead, Stauffer donated his mother's body to the Biological Resource Center in Arizona in hopes neurologists would study what caused her disease, KABC reports. However, he recently learned that his mother's body was then sold to the U.S. military for "blast testing" and was strapped to a chair as an expolsive device was detonated beneath.